Replies to post #89216 on Biotech Values

[DewDiligence]

GNVC has always had an eclectic collection of assets; case in point: AdPEDF gene therapy for age-related macular degeneration (#msg-9296623). AdPEDF proved to be inferior to Lucentis, and the program was quietly shelved in 2006 (#msg-11692299, #msg-12532545).

[flatlander_60048]

I'm a former shareholder of GNVC and a current shareholder of NVS. Seems like I recall the 1st press releases about GNVC's hearing loss treatment more than 2 years ago. In that time they have not moved the treatment into clinical trials. Obviously GNVC's cash was being directed to TNF Pancreatic cancer treatment and at the time it was also being evaluated for cancer of the esophagus.

What surprises me is that one of the few potential treatments for an indication with huge unmet need would go unpartnered for so long. My impression is that NVS is buying a lottery ticket (a longer shot than most partner agreements).

Any thoughts.

FL

[DewDiligence]

GNVC: According to yesterday’s SEC filing, NVS’ $2M of equity was acquired at the discounted price of $1.07/sh:

http://sec.gov/Archives/edgar/data/934473/000114420410002495/v171639_8k.htm